1. Calcium ion antagonist, regulates calcium ion influx on the cell membrane of myocardial conduction cells, myocardial contractile cells and arterial smooth muscle cells, but does not change serum calcium concentration. 2. Dilates the main coronary artery and arterioles, antagonizes coronary artery spasm, increases myocardial oxygen delivery, and reduces myocardial oxygen consumption. 3. Prolongs the effective refractory period of the atrioventricular node, slows conduction, and reduces the ventricular rate of patients with chronic atrial fibrillation and atrial flutter. 4. Produces a hypotensive effect by reducing vascular resistance in the systemic circulation. 5. Reduces afterload, inhibits myocardial contraction, and improves left ventricular diastolic function. 6. Animal experiments show that the local anesthetic effect is 1.6 times that of procaine equimolar, but the human effect and dosage are still unclear.

This product is a new type of fluoroquinolone antibacterial drug. It achieves antibacterial effect by inhibiting the activity of bacterial DNA helicase and topoisomerase IV, hindering bacterial DNA replication. It is effective against aerobic bacteria, general anaerobic bacteria, and anaerobic Gram-positive bacteria and Gram-negative bacteria. It has a killing effect on Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus, and also has strong antibacterial activity against antibiotic-resistant bacteria such as imipenem, cefazolin, ceftazidime, and ampicillin.

Extract from the above information

Omeprazole is a racemic mixture of a pair of active optical enantiomers. It reduces gastric acid secretion through a highly targeted mechanism of action and is a special inhibitor of the acid pump in gastric parietal cells. This product acts rapidly, and a once-daily dose can reversibly inhibit gastric acid secretion. Omeprazole is a weakly alkaline substance that is concentrated and converted into active substances in the highly acidic environment of the tubules in the gastric parietal cells, inhibiting H, K-ATPase (proton pump). This inhibitory effect on the final step of gastric acid formation is dose-related and highly inhibits basal gastric acid secretion and irritant gastric acid secretion, but has nothing to do with irritants. Omeprazole combined with antibiotics can eradicate Helicobacter pylori, which is associated with rapid relief of symptoms, high gastric mucosal repair rate, and long-term relief of peptic ulcer disease, thereby reducing complications such as gastrointestinal bleeding, and also reducing the need for long-term treatment with anti-acid drugs.